News Center

Bionime Corporation (4737) Signed Agreement with GE.

Bionime Corporation (4737) Signed Agreement with GE. To Which item it meets: Article 2 paragraph 10(TWSE Procedures for Verification and Disclosure of Material Information of Companies with Listed Securities) Date of announcement: March 16th, 2011 Descriptions: Date of Event March 16th, 2011…

Bionime has won the PTPA

Bionime has won the PTPAI SAN DIEGO – June 30th, 2010 – Bionime is excited to announce that it has been awarded the influential PTPA Media Inc’s Seal of Approval for excellence in family products. Consumers looking for practical, high-quality products…

Bionime Rightest Series Do Not Use GDH-PQQ

Bionime Rightest Series Do Not Use GDH-PQQ Bionmie RightestTM Series Do Not Use GDH-PQQ, the Enzyme that FDA Issued a Public Health Notification on Potentially Fatal Errors with Glucose Monitoring TechnologyAugust 19, 2009 -Bionime today announced that its RightestTM Series Blood Glucose…

Ypsomed AG, Burgdorf acquires 10 % equity stake in Bionime Corp

Ypsomed AG, Burgdorf acquires 10 % equity stake in Bionime Corp. Bionime Corporation proudly announces a joint co-operation with Ypsomed AG, Switzerland. Ypsomed is a worldwide leading independent developer and manufacturer of injection systems for custom-made self-administration and supplier of…

Bionime GM100 series acquires “Innovation Award” from Mediphar Taipei

Bionime GM100 series acquires “Innovation Award” from Mediphar Taipei 8 winners chosen from a pool of 39 candidates! Bionime RightestTMGM100 series acquires “Innovation Award” from Mediphar Taipei and becoming the only one winner who targets the field of Self-Monitoring Blood Glucose…